Skip to content
You are now leaving https://www.ionispharma.com to visit

Ionis Licenses New Antisense Drug for Kidney Disease to AstraZeneca

Ionis earns $30 million license fee CARLSBAD, Calif. , Feb. 20, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has licensed IONIS-AZ5-2.5 Rx (AZD2373) to the global, science-led biopharmaceutical company AstraZeneca (NYSE: AZN).